It supports all Mounjaro and Zepbound doses (2.5mg to 15mg), shows drug concentration curves based on tirzepatide's pharmacokinetics, and uniquely supports microdosing protocols
semaglutide, a modified GLP-1 peptide with no abuse potential, is not a DEA-controlled substance and therefore not a target of those panels
Ozempic is FDA-approved for diabetes
Recent studies, including new research published in Nature Medicine (Jan 2025), suggest that these medications carry risks beyond short-term nausea or digestive issues
A reliable provider offers quality packaging solutions and works with your needs to build tailored solutions
Capacity Constraints: Device manufacturers may face bottlenecks due to sudden volume increases, particularly for components such as: Medical-grade polymers (e.g., polypropylene) Needles and cannulas Glass cartridges Supplier Concentration Risk: The market remains consolidated, with a limited number of suppliers dominating auto-injectors and pen systems
